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MelanomaNOTCH receptors regulate cell proliferation and survival in several types of cancer cells. Depending on the cellular
context, NOTCH1 can function as an oncogene or as a tumor suppressor gene. DLK1 is also involved in the regu-
lation of cell growth and cancer, but nothing is known about the role of DLK2 in these processes. Recently, the
proteins DLK1 and DLK2 have been reported to interact with NOTCH1 and to inhibit NOTCH1 activation and
signaling in different cell lines. In this work, we focused on the role of DLK proteins in the control of melanoma
cell growth, where NOTCH1 is known to exert an oncogenic effect. We found that human DLK proteins inhibit
NOTCH signaling in SK-MEL-2 metastatic melanoma cells. Moreover, the proliferation rate of these cells was
dependent upon the level of NOTCH activation and signaling as regulated by DLK proteins. In particular, high
levels of NOTCH inhibition resulted in a decrease, whereas lower levels of NOTCH inhibition led to an increase
inmelanoma cell proliferation rates, both in vitro and in vivo. Finally, our data revealed additive NOTCH-mediated
effects of DLK proteins and the γ-secretase inhibitor DAPT on cell proliferation. The data presented in this work
suggest that a ﬁne regulation of NOTCH signaling plays an important role in the control of metastatic melanoma
cell proliferation. Our results open the way to new research on the role of DLK proteins as potential therapeutic
tools for the treatment of human melanoma.
© 2014 Elsevier B.V. All rights reserved.1. Introduction
The evolutionarily conserved NOTCH signaling pathway plays a
critical role in many cell processes, including cell proliferation. In mam-
mals, NOTCH signaling is triggered by the interaction of a membrane
receptor (NOTCH1-4) with a DELTA or JAGGED canonical ligand. This
induces metalloproteinase-mediated and γ-secretase-mediated cleav-
age of the NOTCH receptor, which releases an active NOTCH intracellu-
lar domain (NICD). NICD translocates to the nucleus and forms a
complex with CBF-1/RBP-Jκ, a factor mediating the transcription of
target genes, such as the HES/HEY family of transcription factors,
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range of tumor types. However, NOTCH-dependent tumor suppressor
effects have been also reported. Today it is becoming clear that the
NOTCH1 receptor can act both as an oncogene and as a tumor suppres-
sor depending on the cellular context, its level of expression, and cross-
talking with other signaling pathways [2–6]. However, how activation
of a single pathway gives rise to these opposite outcomes is not fully
understood.
It has been reported that NOTCH1 signaling plays a dual opposite
role in some skin cancers. Several studies support a tumor suppressor
role of NOTCH1 signaling in non-melanoma skin cancer [5]. In contrast,
active NOTCH1 is expressed in humanmelanoma and it is able to trans-
form primary melanocytes in vitro and to promote progression of
primary melanoma towards an advanced stage [7–10]. Previous studies
have revealed several potential downstream pathways, including
MCAM, N-cadherin, B-catenin,MAPK, and PI3K–AKT pathways, mediat-
ing the oncogenic effects of NOTCH signaling in melanoma cells [9–12].
These data support an oncogenic role for NOTCH signaling inmelanoma
and highlight the potential of inhibiting the NOTCH pathway as a ther-
apeutic approach for the treatment of this prevalent tumor [13–15].
DLK1 and DLK2 are also members of the EGF-like repeat-containing
family of proteins, which includes NOTCH receptors and their ligands.
DLK1 functions both as a transmembrane and as a secreted protein.
An increasing body of evidence indicates that both, membrane or
2675M.-L. Nueda et al. / Biochimica et Biophysica Acta 1843 (2014) 2674–2684secreted, forms of DLK1 interact with NOTCH1 and act as negative reg-
ulators of NOTCH activation and signaling [16,17]. Recently, it has
been reported that DLK2 also interacts with NOTCH1 and inhibits
NOTCH signaling [18]. DLK1 is involved in a variety of processes, includ-
ing differentiation, cell proliferation and tumorigenesis [19–28]. In fact,
it has been reported that DLK1 may also function both as an oncogenic
and as an anti-oncogenic factor [20,29–31]. DLK2 also participates in
the regulation of adipogenic differentiation, as DLK1 does [32]. The pos-
sible functional effects of DLK2 expression in tumorigenesis and cell
growth are still unknown.
The role of NOTCH signaling in melanoma prompted us to analyze
the effects of DLK proteins on melanoma NOTCH signaling and cell pro-
liferation. In this study, we provide extensive evidence supporting that,
in agreement with previous reports involving other cell types, DLK
proteins can regulate also NOTCH signaling inmelanoma cells. Interest-
ingly, this can lead to opposite effects in metastatic melanoma growth,
depending upon the ﬁnal NOTCH activation levels. Our results suggest
that both DLK proteins could be potentially interesting to be used,
alone or together with other NOTCH inhibitors, such as DAPT, to regu-
late the growth of metastatic human melanoma cells by modulating
NOTCH activation and signaling.
2. Materials and methods
2.1. Plasmids
The plasmid HDLK1S contains the entire human DLK1 cDNA from
plasmid HDLK1-AG1 [33]. HDLK1-AG1 was digested with HindIII-NotI
restriction enzymes and the puriﬁed cDNA-containing fragment was
cloned into the HindIII-NotI restriction sites of the pLNCX2 expression
vector (Clontech, Palo Alto, CA, USA). Plasmid HDLK2S contains the en-
tire human DLK2 cDNA (MGC Full-Length clone IMAGE ID 54954558).
HDLK2 cDNA from the MGC clone was isolated by digestion with
HindIII-NotI restriction enzymes and subsequently cloned into the
HindIII-NotI restriction sites of pLNCX2. HDLK2aS derives from the
same IMAGE clone. In this case, HDLK2 cDNA was isolated by digestion
with NotI-SalI restriction enzymes and cloned into the NotI-SalI restric-
tion sites of pLNCX2 in antisense orientation.
2.2. Cell culture and transfection conditions
The human metastatic melanoma cell line SK-MEL-2 was acquired
from American Type Culture Collection (HTB-68) and cultured at
37 °C in a 5% CO2 humidiﬁed atmosphere, with Dulbecco's modiﬁed
Eagle's medium containing 10% fetal bovine serum (FBS) (Lonza,
Verviers, Belgium). Transfections were performed with 80% conﬂuent
cells, using a 6:2 ratio of FUGENE HD Transfection Reagent and plasmid
DNA, respectively, following the manufacturer's recommendations
(Roche Diagnostics GmbH, Mannheim, Germany). Stable transfectants
were selected under standard culture conditions in a selective medium
containing 750 μg/ml of G418 (Sigma, St. Louis, MO, USA). Conditioned
media were obtained either fromHDLK1S or pLNCX2 stably transfected
SK-MEL-2 cells. The conditioned media were dialyzed against complete
newmediumby using Centricon YM-100 (Millipore, Carrigtwohill, IRL).
In some cases, the cells were treated with increasing concentrations of
γ-secretase inhibitor IX (DAPT) (Calbiochem, San Diego, CA, USA) or
DMSO, as a control.
2.3. Cell growth assays
Cell proliferation was measured by MTT assays according to the
manufacturer's protocol (Sigma). We seeded 1000 cells per well in a
96-well plate, and the medium was replaced every 2 days. In some
cases, the cells were cultured in conditioned medium from either HDLK1S
or pLNCX2 stably transfected SK-MEL-2 cells. To study the effects of the
γ-secretase inhibitor IX (DAPT) on cell proliferation, cells were treatedwith the indicated concentrations of DAPT or DMSO, as a control. Prolifera-
tion assays were carried out for the days indicated in the ﬁgures.
2.4. RNA extraction and RT-qPCR
For gene expression analysis, cell monolayers were washed twice
with PBS and detached with Trypsin/Versene (Lonza). Cells were then
collected by centrifugation (180 ×g, 5 min, at 4 °C) and washed twice
with PBS. Total RNA was isolated by using the RNeasy Kit (Qiagen,
Chatsworth, CA, USA). Following DNase treatment (Qiagen), RNA
(1 μg) was reverse-transcribed by using the cDNA RevertAid™
Minus First Strand kit (Fermentas, Madrid, Spain), according to the
manufacturer's recommendations. To perform RT-qPCR, cDNA was
PCR-ampliﬁed by using the SYBR-GREEN Master Mix and ABI
PRISM 7500 Fast Real-Time PCR System (Applied Biosystems, Carls-
bad, CA, USA). The PCR conditions used were: initial denaturation
step at 95 °C, followed by 30 s at 60 °C. GADPH expression was
used as a control to compare the CT from the different samples. The
primers used for determining the expression level of HES1, HEY1,
and HEY2 were previously described [8]. The primers used for deter-
mining the expression level of p21WAF1/Cip1 (H_CDKN1A_1) and cyclin
D1 (H_CCND1_1) were the predesigned SYBR® Green I Primers used
for RT-qPCR (Sigma): FH1_CDKN1A: 5′ CAG CAT GAC AGA TTT CTA
CC 3′, as the p21 upper primer, and RH1_CDKN1A: 5′ CAG GGT ATG
TAC ATG AGG AG 3′, as the p21 lower primer, FH1_CCND1: 5′ GCC
TCT AAG ATG AAG GAG AC 3′ as the cyclin D1 upper primer, and
RH1_CCND1: 5′ CCA TTT GCA GCA GCT C 3′ as the cyclin D1 lower
primer. The primers employed for determining the expression level
of GAPDH were: GAPDHup; 5′ CAA TGA CCC CTT CAT TGA CC 3′, as
the upper primer, and GAPDHlow; 5′ GAT CTC GCT CCT GGA AGA
TG 3′, as the lower primer.
2.5. Western blot
For protein expression, cell pellets were lysed in RIPA buffer and
incubated at 4 °C for 30 min. Protein content of cleared lysates was
quantiﬁed, and 100 μg of total protein extract or conditioned medium
were loaded into 12% (w/v) SDS-PAGE gels. Western blot was per-
formed as described previously [34] by using the following antibodies:
anti-DLK1 [16], diluted 1:2000; anti-DLK2 (Abnova, Heidelberg,
Germany), diluted 1:500; anti-cleaved NOTCH1 (Val 1744, Cell Signal-
ing, Beverly, MA, USA), diluted 1:500; anti-NOTCH1 (C-20; Santa Cruz
Biotechnologies, Santa Cruz, CA, USA), diluted 1:1000: and anti-
tubulin (Sigma), diluted 1:5000. Densitometry analyses of Western
blot signals were made by using Quantity One 1D analysis software
(Bio-Rad, Munchen, Germany).
2.6. Luciferase assays
To measure NOTCH transcriptional activity, SK-MEL-2 cells
were co-transfected with pGLucWT and combinations of the DLK1
or DLK2 expression plasmids under study. pGlucWT was used for
determining CBF1-dependent promoter activity, using luciferase
as a reporter gene. pGlucWT contains the luciferase reporter gene
under the control of four copies of the CBF1 recognition site se-
quence cloned upstream of the SV40 promoter in the vector pGL3
[34]. To analyze NOTCH basal transcriptional activity in stable
transfectants, these cells were only transfected with plasmid
pGLucWT and the luciferase activity was determined. To measure
the inhibition of NOTCH transcriptional activity caused by DAPT,
pLNCX2-transfected cells were transfected with pGLucWT and in-
cubated in the presence of different concentrations of DAPT for
24 h, and then, the luciferase activity was measured. To normalize
the data obtained, cells were also transfected with pRLTK (renilla
expression plasmid). In all these luciferase assays, cells were
lysed and processed using the dual luciferase kit (Dual-Luciferase
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transfection. These assays were repeated at least three times.
2.7. Animal experiments
Female Athymic Nude-Foxn1nu mice (5-week-old) were supplied by
Harlan Laboratories (Barcelona, Spain). 5 × 106 SK-MEL-2 cells stably
transfected with empty vector or with plasmids HDLK1S or HDLK2S
were injected subcutaneously in the dorsal ﬂanks of mice for a total of 5
mice per group. Mice were sacriﬁced 45 days after injection. Tumors
were measured and tumor size was calculated using the following
formula: length (mm) × width (mm). In vivo experiments were
performed in accordancewith Spanish and European regulations, and ap-
proved by the University of Castilla–La Mancha Animal Care and Use
Committee.
2.8. Statistical analysis
Data are presented as mean ± SD of two different cell transfectants
for each construct, in at least three independent assays performed by
triplicate. Data were also analyzed with GraphPad and/or SPSS software
to perform the two-tailed Student's t test or the Mann–Whitney U test
to determine statistical signiﬁcance relative to pLNCX2 (empty vector)
transfected cells or non-treated cells. A P value of≤0.05was considered
statistically signiﬁcant (*); a P value ≤0.01 was considered highly
statistically signiﬁcant (**); and a P value of ≤ 0.001 was considered
extremely statistically signiﬁcant (***).
3. Results
3.1. Overexpression of human DLK1 or DLK2 proteins is associated with
increased SK-MEL-2 melanoma cell growth
To study the hypothetical involvement of DLK proteins on meta-
static melanoma cell proliferation, we ﬁrst modiﬁed DLK1 or DLK2
expression levels in SK-MEL-2 cells, which lack endogenousDLK1 ex-
pression, but express DLK2. We stably transfected SK-MEL-2 cells
with the empty vector (pLNCX2), sense DLK1 (HDLK1S), or sense or
antisense DLK2 cDNA (HDLK2S, HDLK2aS) expression constructs. A
minimum of two different stable transfectants from each construct
was used in all experiments. We analyzed DLK1 and DLK2 expression
in our stable transfectants by RT-qPCR (data not shown). By using
Western blot, we conﬁrmed that SK-MEL-2 cells transfected with
sense DLK1 (HDLK1S) or DLK2 (HDLK2S) expression constructs
overexpressed DLK1 or DLK2 proteins, respectively, and that SK-
MEL-2 cells stably transfected with antisense DLK2 (HDLK2aS)
showed decreased DLK2 expression levels (Fig. 1A). To test the ef-
fects of DLK protein expression on melanoma growth, we performed
cell proliferation assays. Overexpression of DLK1 or DLK2 in SK-MEL-
2 melanoma cells signiﬁcantly enhanced their proliferation rates,
whereas diminished expression of DLK2 inhibited the proliferation
of these cells compared to non-transfected parental cells or empty
vector-transfected cells (Fig. 1B).
Cell proliferation is tightly regulated by expression and modula-
tion of cell cycle-dependent cyclins, CDKs, and CDK inhibitors. To
explore the underlying mechanism of increased cell proliferation
induced by DLK1 and DLK2 proteins, we analyzed their effects on
the expression levels of the cyclin-dependent kinase inhibitor
p21WAF1/Cip1 and cyclin D1, since it has been previously reported
that DLK1 modulates their expression in some cell types [25,30].
As shown in Fig. 1C, a signiﬁcant decrease in p21WAF1/Cip1 expres-
sion and an increase in cyclin D1 expression, relative to control
cells transfected with the empty vector, were detected in SK-
MEL-2 cells stably transfected with HDLK1S or HDLK2S plasmids.
As expected, downregulation of DLK2 expression increased
p21WAF1/Cip1 expression and decreased cyclin D1 expression. Theseresults support a role of DLK proteins in melanoma cell
proliferation.
Taking into consideration our data indicated that DLK proteinsmod-
ulate in vitro cell growth of SK-MEL2 melanoma cells, we therefore
analyzed whether they could affect in vivo SK-MEL2melanoma growth.
To investigate this, we injected in nude mice, subcutaneously, 5 × 106
SK-MEL-2 cells stably transfected with the empty vector or with
plasmids HDLK1S or HDLK2S, and monitored the tumor size on the
days indicated in Fig. 2. The results showed that, as expected, SK-MEL-
2 cells stably transfected with the empty vector did not develop signif-
icant tumors in vivo. However, an increase in tumor cell growth was
observed in HDLK1S or HDLK2 stable SK-MEL-2 transfectants, as
compared to the control (Fig. 2A). Comparison of tumor size on day
45 after inoculation also indicated that the tumors that ﬁnally devel-
oped from DLK1 or DLK2-overexpressing melanoma cells were signiﬁ-
cantly larger than those generated by the control cells (Fig. 2B). These
results demonstrate an in vivo oncogenic effect of DLK proteins in
melanoma cells.
As DLK1 functions both as a transmembrane and as a secreted
protein, we decided to analyze the effect of soluble DLK1 protein on
SK-MEL-2 melanoma cell proliferation. SK-MEL-2 cells stably
transfected with empty vector or with HDLK1S or HDLK2S plasmids
were grown inHDLK1S conditionedmediumor vector (pLNCX2) condi-
tioned medium (Materials and methods; Fig. 3A). As expected, the
proliferation rate of empty vector-transfected control cells was en-
hanced in the presence of DLK1-enriched medium as compared to the
same cells grown in conditioned medium from control cells (Fig. 3B).
However, adding DLK1-enriched conditioned medium to HDLK1S or
HDLK2S stable transfectants signiﬁcantly inhibited their proliferation
rates (Fig. 3C and D). These results demonstrate that the levels of
DLK2 and soluble or transmembrane DLK1 proteins are able to modu-
late melanoma cell proliferation.
3.2. DLK1 and DLK2 proteins inhibit NOTCH activation and signaling in
human metastatic SK-MEL-2 melanoma cells
DLK1 and DLK2 have been reported to interact withNOTCH1 and in-
hibit NOTCH signaling [18]. Considering that NOTCH signalingmay play
an important role in melanoma progression, we studied whether
human DLK1 and DLK2 also acted as NOTCH signaling inhibitors in
metastatic melanoma cells. As shown in Fig. 4A, overexpression of
DLK1 or DLK2 in SK-MEL-2 melanoma cells signiﬁcantly inhibited
NOTCH1 activation, whereas a decrease in DLK2 expression resulted
in an increase of NOTCH1 activation. As a control, we treated vector-
transfected cells with the γ-secretase inhibitor DAPT (10 μM) for 24 h,
a treatment known to suppress NOTCH activation. In addition, we ana-
lyzed NOTCH-dependent transcriptional activity, as measured by lucif-
erase assays, in SK-MEL-2 stably transfected with plasmids HDLK1S,
HDLK2S or HDLK2aS, and transiently transfected with plasmid
pGLucWT. Overexpression of either DLK1 or DLK2 resulted in the inhi-
bition of NOTCH signaling (Fig. 4B). However, we did not detect signif-
icant changes in NOTCH activation levels in SK-MEL-2 cells with
decreased levels of DLK2.We also conﬁrmed the effects of DLK proteins
on NOTCH signaling by analyzing the expression levels of the NOTCH
target genesHES1,HEY1 and HEY2 by RT-qPCR (Fig. 4C). The expression
of these genes by HDLK1S or HDLK2S stably transfected cells was
signiﬁcantly reduced, whereas their expression levels in HDLK2aS
transfectants were increased, thus conﬁrming the inhibitory effects of
DLK1 and DLK2 on NOTCH signaling.
The potential effects of DLK1 or DLK2 on NOTCH activation and
signaling were analyzed also by co-transfecting SK-MEL-2 cells
with plasmid pGLucWT and different amounts of plasmids
HDLK1S and/or HDLK2S. As shown in Fig. 5A, overexpression of
DLK1 and/or DLK2 proteins decreased NOTCH signaling. Besides,
overexpression of DLK1 inhibited NOTCH signaling in a dose-
dependentmanner. Finally, we further analyzed NOTCH transcriptional
Fig. 1.Overexpression of humanDLK1 orDLK2 proteins promotes SK-MEL-2 cell proliferation. (A) SK-MEL-2 cells were stably transfectedwith empty vector or plasmidsHDLK1S, HDLK2S
or HDLK2aS. RepresentativeWestern blot analysis (left) and densitometry analysis (right) for human DLK1 (~42 kDa) and DLK2 (~42 kDa) protein expression are shown. Data were nor-
malized with tubulin (~50 kDa) expression levels, used as a loading control. (B) Cell growthmeasured by MTT assays. The graph shows the percentage of cell growth (mean± SD) of the
indicated transfectants as comparedwith that of vector cells (adjusted to 100%) after 7 days of culture. NT: non-transfected cells. Datawere obtained from two different stable transfectants
in three independent experiments. (C) Level of expression of the cell cycle genes p21WAF1/Cip1 and cyclin D1 in SK-MEL-2 cells stably transfected with HDLK1S, HDLK2S or HDLK2aS. Data
were normalized to GAPDH mRNA levels in RT-qPCR assays. Student's t-test results relative to vector cells: *(P b 0.05), **(P b 0.01), ***(P b 0.001).
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expressing plasmids, transiently transfected with plasmid pGLucWT,
and cultured in conditioned medium from vector or HDLK1S-
transfected cells. As expected, DLK1-enriched conditioned medium
inhibited NOTCH signaling. Moreover, this inhibition was stronger incells overexpressing DLK1 or DLK2 proteins, as compared to control
cells transfected with the empty vector (Fig. 5B). These results
demonstrate that DLK proteins are able to inhibit NOTCH activation
and signaling in a dose-dependent manner in metastatic melanoma
cells.
Fig. 2. SK-MEL2 cells overexpressing human DLK1 or DLK2 promote tumor cell growth in vivo. (A) SK-MEL-2 cells stably transfected with empty vector or plasmids HDLK1S or HDLK2S
were injected s.c. into nudemice. Tumor sizewasmeasured at the indicated times (days). Results indicated are themean±SD. (B) The graph shows themean±SDof the tumor diameters
at the endpoint of the experiment.Mann–WhitneyU test results relative to vector cells injectedmice: *(P b 0.05). (C)Micewere sacriﬁced after 45 days and photographed. Representative
photographs of skin tumor formed in mice from each group are shown.
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human metastatic melanoma SK-MEL-2 cells
Previous studies have shown that the suppression of NOTCH activa-
tion and signaling with γ-secretase inhibitors (GSIs) decreases the
proliferation rate of melanoma cell lines in a dose-dependent manner,
leaving melanocyte growth unaltered [8]. Moreover, it has been
described that treatment of melanoma cell lines with a low dose of
DAPT (0.2 μM), suppressed primary melanoma cell proliferation, but
did not affect the proliferation of metastatic melanoma cells [9]. To fur-
ther investigate the role of DLK proteins on NOTCH1 activation and
melanoma cell proliferation, we examined the effects of different
concentrations of DAPT in our different transfected cells. As shown in
Fig. 6A, treatment of control SK-MEL-2 cells with a high dose of DAPT
(2.5 μM) led to a drastic decrease of active NOTCH1, as compared to
the levels of active NOTCH1 in cells treated with lower doses of DAPT
(0.1 μMor 1.0 μM).We also analyzedNOTCH-dependent transcriptional
activity in SK-MEL-2 cells transiently co-transfected with plasmid
pGLucWT and empty vector, or with plasmids HDLK1S, HDLK2S or
HDLK2aS, and treated with different concentrations of DAPT. As
shown in Fig. 6B, any dose of DAPT, and either DLK1 or DLK2 overex-
pression, signiﬁcantly decreased, but downregulation of DLK2 expres-
sion increased, NOTCH-dependent transcriptional activity as measured
by luciferase activity assays. Moreover, our results indicate that
treatment of SK-MEL-2 cells with a low dose of DAPT (0.1 μM or 1.0
μM) led to a similar level of NOTCH signaling inhibition as that shown
by SK-MEL-2 cells overexpressing DLK1 or DLK2.
To investigate the dose-dependent effects of DAPT and DLK protein
levels on NOTCH activation, we treated SK-MEL-2 cells stably
transfected with DLK1 or DLK2-expressing plasmids with two different
concentrations of DAPT and analyzed the active NOTCH1 levels byWestern blot. As shown in Fig. 6C, the treatment of HDLK1S or
HDLK2S stable transfected cells with either a high (2.5 μM), or a low
(1.0 μM) dose of DAPT led to complete NOTCH1 inhibition. We also
analyzed these effects by measuring the NOTCH-dependent transcrip-
tional activity in SK-MEL-2 cells overexpressing DLK1 or DLK2, and
treated, or not, with 2.5 μM or 1.0 μM DAPT. As shown in Fig. 6D, the
inhibition of NOTCH-dependent transcriptional activity in cells overex-
pressing DLK1 or DLK2 and treated with DAPT was stronger than that
obtained in control cells or in non-treated HDLK1S or HDLK2S stable
transfectants.
3.4. Effects of DAPT treatment and increased DLK protein expression on SK-
MEL-2 cell proliferation
To investigate the dose-dependent effects of the above treatments
on metastatic melanoma cell proliferation, we ﬁrst analyzed by MTT
assays the cell proliferation rate of SK-MEL-2 cells in the presence of in-
creasing concentrations of DAPT. The treatment of these cells with a
high dose of DAPT (2.5 μM) signiﬁcantly reduced their proliferation
rate. Surprisingly, low doses of DAPT (0.1 μM or 1.0 μM) signiﬁcantly
enhanced their proliferation rate (Fig. 7A). Then,we analyzed the prolif-
eration rate of SK-MEL-2 cells stably transfected with plasmids HDLK1S
or HDLK2S and treated, or not, with 2.5 μMor 1.0 μMDAPT. As shown in
Fig. 7B and C, treatment of HDLK1S or HDLK2S stable transfectants with
either dose of DAPT signiﬁcantly inhibited their proliferation rates.
Taken together these results suggest that treatment of SK-MEL-2 mela-
noma cells overexpressing DLK1 or DLK2 with a low dose of DAPT leads
to a more effective inhibition of cell proliferation than that obtained in
cells transfected with empty vector and treated with any dose of
DAPT, or cells overexpressing DLK1 or DLK2 not treated with DAPT.
Thus, our data suggest that treatment of human metastatic melanoma
Fig. 3. Conditionedmedium containing human DLK1 promotes the proliferation of SK-MEL-2 cells, but inhibits that of SK-MEL-2 cells overexpressing DLK1 or DLK2 proteins. (A)Western
blot analysis of soluble DLK1 protein (~38 kDa) in conditionedmedium from SK-MEL-2 cells stably transfectedwith empty vector (Vector C.M) or HDLK1S plasmid (DLK1S C.M). The pro-
liferation rate of SK-MEL-2 cells stably transfectedwith empty vector (B), plasmidHDLK1S (C) or plasmidHDLK2S (D), in thepresence of Vector C.M. or HDLK1S C.M., at the indicated times
(days), wasmeasured byMTT assays. Each graph shows themean± SD of two different transfectants, in at least three independent experiments. The number of cells at the different time
points was normalized to the number of cells at time zero, set arbitrarily at 1. Student's t-test results relative to vector cells: *(P b 0.05), **(P b 0.01), ***(P b 0.001).
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effective at inhibiting NOTCH signaling and cell proliferation than
treating these cells with each one of these inhibitory agents separately.4. Discussion
In this report, we show that the effects of the proteins DLK1 and
DLK2 on metastatic melanoma cell growth depend upon their levels of
expression and the levels of NOTCH signaling inhibition generated by
them or their combined treatment with NOTCH signaling inhibitors,
such as DAPT. In ourﬁrst assays, we observed that ectopically expressed
DLK1 or DLK2 signiﬁcantly enhanced the proliferation rate of human
metastatic melanoma SK-MEL-2 cells, as determined by MTT assays,
compared to empty vector-transfected cells. Related to these results,
the effects of DLK1 on SK-MEL-2 cell proliferation appear to be consis-
tent with recent studies indicating that overexpression of DLK1
promotes proliferation of some tumor cell lines [25,29,30]. However,
our ﬁndings contradict other studies where DLK1 has been shown to
exert inhibitory effects on the proliferation of other cell types [20,27,
28,35]. On the other hand, SK-MEL-2 cells with diminished levels of
DLK2 expression, obtained by antisense transfection, showed decreased
proliferation rates by MTT assays, compared to empty vector-
transfected cells. To our knowledge, this is the ﬁrst report in the litera-
ture describing a role of DLK2 in the control of cell proliferation.It has been previously reported that the upregulation of p21 and the
decrease in cyclin D1 expression contribute to G1 cell cycle arrest in SK-
MEL-2 cells [36,37]. Similarly, we have observed that the overexpres-
sion of DLK1 or DLK2 in these cells signiﬁcantly decreased p21WAF1/Cip1
expression and increased cyclin D1 expression, whereas lower levels
of DLK2 expression resulted in an increase in p21WAF1/Cip1 expression
and a decrease in cyclin D1 expression. These results agree with other
published reports showing that DLK1-overexpressing human hepato-
cellular carcinoma cells decreased p21WAF1/Cip1 expression and induced
cell proliferation [30]. Yin and colleagues [25] found that DLK1 promot-
ed glioblastoma cell proliferation and increased the expression of
proliferation-enhancing proteins, such as cyclin D1. In contrast, forced
expression of DLK1 in human erythroid leukemia cells enhanced their
proliferation rates, but no difference was detected in levels of Rb, cyclin
D1, and p21 proteins [38]. Our results suggest that DLK proteins could
induce melanoma cell proliferation through changes in the expression
of key cell cycle regulators, such as p21WAF1/Cip1 and cyclin D1.
Although SK-MEL-2 cells do not form tumors well in nudemice [39],
we decided to perform a tumor growth assay in these animals to
analyze whether DLK proteins could promote melanoma cell growth
in vivo, as they do in vitro. In the present study we observed that SK-
MEL-2 cells overexpressing either DLK1 or DLK2 and subcutaneously
implanted in nude mice, increased tumor growth in vivo, compared to
mice inoculated with cells transfected with the empty vector. This ﬁnd-
ing agrees with other authors who showed that the overexpression of
Fig. 4. Overexpression of human DLK1 or DLK2 proteins inhibits NOTCH1 activation and signaling in SK-MEL-2 cells. (A) Representative Western blot analysis (left) for active NOTCH1
(active NICD1 ~ 110 kDa) in SK-MEL-2 cells stably transfected with empty vector or plasmids HDLK1S, HDLK2S or HDLK2aS. SK-MEL-2 cells treated with 10 μM DAPT for 24 h were
used as a control. NICD1 expression was normalized to total NOTCH1 expression (~120 kDa) and data were ﬁnally normalized to those of cells transfected with the empty vector.
These data were represented in the graph (right) as the mean ± SD of two different transfectants for each construct, in at least three independent experiments. The empty vector
transfectants are the reference control for cells transfected both with DLK1 and with DLK2 expressing plasmids. (B) Analysis of NOTCH transcriptional activity, as measured by luciferase
assays, in SK-MEL-2 stably transfected with empty vector or plasmids HDLK1S, HDLK2S or HDLK2aS, and transiently transfected with plasmid pGLucWT, which expresses a NOTCH-
dependent luciferase reporter gene. The relative luciferase activity was calculated by normalizing data to those obtained from cells transfectedwith the empty vector and it is represented
as themean± SD of two different transfectants for each construct, in at least three independent experiments. (C) Level of expression of the NOTCH target genes HES1, HEY1 and HEY2, in
HDLK1S,HDLK2S orHDLK2aS stably transfected SK-MEL-2 cells. Datawere normalized toGADPHmRNA levels in quantitative RT-PCR assays. Student's t-test results relative to vector cells:
*(P b 0.05), **(P b 0.01), ***(P b 0.001).
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trary, other studies have shown that expression of exogenous DLK1
could inhibit in vivo tumor growth [20,42]. Our current ﬁndings support
that DLK could be oncogenic in some tumor types and tumor suppressor
in others, probably depending on their protein expression levels and the
effects of DLK on NOTCH signaling in each tumor type.
DLK1was previously shown to act both as a transmembrane and as a
soluble protein [16,25], but nothing is known so far aboutwhether DLK2
is also secreted or not. As expected, the results obtained by using
conditioned media are consistent with DLK1 being released to the
extracellular medium of SK-MEL-2 cells stably transfected with a
DLK1-expressing plasmid. As we observed in DLK1 or DLK2 stable
transfectants, we found that the growth rate of metastatic melanoma
control cells (transfected with the empty vector) was signiﬁcantly in-
creased in the presence of conditioned medium from DLK1-expressing
cells. Surprisingly, we detected that the addition of conditioned medi-
um, containing soluble DLK1 protein, to HDLK1S or HDLK2S stable
transfectants led to a signiﬁcant inhibition of cell proliferation. These
results indicate that the proliferation rate of SK-MEL-2 cells is highly
sensitive to changes in the concentration or expression levels of DLK
proteins.
The versatile effects of NOTCH signaling on cell differentiation, cell
proliferation, survival, and tumorigenesis have been widely described.
It has been also described that DLK1 and DLK2 proteins act as inhibitors
of NOTCH signaling in other cellular systems [16–18,25]. In this work,we have observed that melanoma cell growth rates depend on the
NOTCH signaling levels. Therefore, we studied the effects of DLK1 and
DLK2 on NOTCH signaling in these cells to investigate whether the
effects of DLK proteins on cell growth are a consequence on their mod-
ulation of NOTCH signaling. We have focused on NOTCH1, which is
overexpressed in melanomas, but our data do not exclude the potential
involvement of other NOTCH familymembers, also expressed in human
melanoma cells [8,43].We have found that forced expression of DLK1 or
DLK2 in these cells led to a decrease in NOTCH1 activation, and HES1,
HEY1 and HEY2 NOTCH-target gene expression. Moreover, the decrease
of DLK2 expression levels in SK-MEL-2 cells led to an increase in both
NOTCH1 activation and the expression of the NOTCH-target genes
analyzed. These data demonstrate the inhibitory effect of DLK1 and
DLK2 on NOTCH activation and signaling in human melanoma cells. In
addition, our data also show that both, human soluble and transmem-
brane DLK1 variants, are able to inhibit NOTCH signaling in melanoma
cells in a dose-dependent manner. To our knowledge, this is the ﬁrst
report describing the NOTCH inhibitory properties of human DLK pro-
teins in tumorigenic cells.
Moreover, very important data obtained in this work are that differ-
ent concentrations of DLK proteins can lead to an increase or to a
decrease of SK-MEL-2 cell proliferation, most likely by inducing differ-
ent levels of NOTCH signaling inhibition. Consistent with our ﬁndings,
it has been reported that different levels of NOTCH signaling exert dif-
ferent effects [2,44]. More surprising is the fact that downregulation of
Fig. 5.NOTCH signaling is inhibited by DLK1 and DLK2 proteins in a dose-dependentman-
ner. (A)Analysis ofNOTCH transcriptional activity, asmeasuredby luciferase assays, in SK-
MEL-2 cells transiently co-transfected with plasmid pGlucWT and empty vector, or the
indicated amounts of plasmids HDLK1S and/or HDLK2S. The relative luciferase activities,
represented as the mean ± SD of three independent experiments, were calculated by
normalizing the data to those obtained from cells transfected with the empty vector.
Student's t-test results are also relative to vector cells values. (B) Analysis of NOTCH tran-
scriptional activity, as measured by luciferase assays, in DLK1 or DLK2 stable SK-MEL-2
transfectants, transfected with plasmid pGlucWT and cultured with HDLK1S conditioned
medium (C.M.) or Vector C.M. The relative luciferase activities were calculated by normal-
izing the data to those obtained from cells transfected with the empty vector and are rep-
resented as the mean ± SD of two different transfectants for each construct, in at least
three independent experiments. Student's t-test results relative to cell samples are indi-
cated in the ﬁgure: *(P b 0.05), **(P b 0.01), ***(P b 0.001).
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signaling, led to an inhibition of the growth rate of SK-MEL-2 cells. We
do not have an explanation for this effect, but DLK2 could also partici-
pate in the regulation of apoptosis, as DLK1 does [20,45]. Besides, we
cannot discard that DLK proteins could target other NOTCH receptors,
and be involved in the regulation of NOTCH receptors, promoting
other effects not described yet. Further studies will be necessary to
determine the role of DLK proteins in the inhibition or not of each indi-
vidual NOTCH receptor. In any case, the data presented here support
that the inhibition of NOTCH activation by DLK proteins modulates
NOTCH signaling and leads to variations in the cell proliferation rates
of human metastatic melanoma cells.
Activation of NOTCH signaling is able to either stimulate or inhibit
proliferation by regulating the cell cycle in a cell type-speciﬁc and
context-dependent manner [46]. The effect of NOTCH signaling on the
regulation of p21WAF1/Cip1 and cyclin D1expressionmay differ in various
tumor cell types. Our results suggest that a slight NOTCH signaling inhi-
bition may be associated with the downregulation of p21WAF1/Cip1 ex-
pression and upregulation of cyclin D1 expression, which could result
in an increase ofmelanoma cell proliferation rate. It has been previously
described that the activation of NOTCH signaling induces p21WAF1/Cip1
expression and downregulates cyclin D1 expression which correlates
with growth inhibition [47]. However, it has also been described that
the cell cycle arrest through upregulation of p21WAF1/Cip1 expression
and/or downregulation of cyclin D1expressionwaspromoted by inhibi-
tion of NOTCH1 signaling in melanoma tumor cells and other cell types
[11,48–52].Interestingly, in this work we have also found that different levels of
NOTCH signaling may cause opposite effects on SK-MEL-2 proliferation
rate. In particular, high levels of NOTCH inhibition resulted in a decrease
of metastatic melanoma cell growth, whereas lower levels of NOTCH
inhibition led to an increase in their cell proliferation rates. As men-
tioned above, we found that DLK proteins, while moderately decreasing
NOTCH signaling levels, promoted the growth of SK-MEL-2 cells,where-
as decreased expression of DLK2 protein, leading to increased NOTCH
signaling, inhibited their proliferation. However, we observed that
high levels of DLK protein expression, associated with a strong inhibi-
tion of NOTCH signaling, led to an inhibition of SK-MEL-2 proliferation.
These data indicate that human DLK1 and DLK2 proteinsmaymodulate
the cell proliferation rate of human metastatic melanoma cells through
the modulation of NOTCH signaling levels.
Recently, enthusiasmhas increased in targeting theNOTCHpathway
using γ-secretase inhibitors (GSIs) because a number of preclinical
studies have shown that GSIs hold promise as a new target-based ther-
apy for tumors in which activated NOTCH signaling is important for
their growth [4,6,13,15,53]. However, one of the major challenges is to
eliminate unwanted toxicity associated with the GSIs. It is important
to note that γ-secretase is a protease enzyme complex with up to one
hundred potential substrates, including NOTCH receptors [13,54,55].
Thus, these side effects may be minimized if agents selective for
NOTCH receptors could be developed [56]. In this regard, our work sug-
gests that products derived from DLK proteins could be used in the
future as novel anti-NOTCH agents with higher speciﬁcity to target
NOTCH signaling than the current γ-secretase inhibitors.
In addition, we show here that low inhibition of NOTCH signaling
may promote cell growth, which implies an unexpected negative effect
that could be a potential additional risk for the patients treated with
NOTCH signaling inhibitors in inadequate doses. Our data indicate that
a high dose of DAPT, a high amount of DLK proteins, or a low DAPT
dose combinedwith a low amount of DLKproteins leads to an inhibition
of the proliferation rate of melanoma SK-MEL-2 cells due to a strong
NOTCH inhibition; however, the treatment of these cells with a low
dose of DAPT or a low amount of DLK proteins leads to a lower reduction
of NOTCH activation and to an increase in their proliferation rate. Thus,
the level of NOTCH signaling appears to be critical for the proliferation
outcome in response to the extracellular signals triggering this process.
These ﬁndings highlight the necessity of a careful evaluation of GSI dose
levels and therapeutic windows to determine the optimal design of
human clinical trials for candidate drugs targeting NOTCH signaling. Be-
sides, the data presented here suggest that an effective therapeutic ap-
proach could involve GSIs treatment in combination with DLK
proteins or derived peptides. In fact, initial trials have shown that GSI
toxicity was dose-limiting [15,57]. Thus, this strategy may offer the ad-
vantage of allowing speciﬁc NOTCH inhibition and potentially minimiz-
ing side effects caused by highly non-speciﬁc GSIs. Finally, recent
investigations in melanoma research have led to the identiﬁcation of
several molecular pathways and speciﬁc gene products that are often
deregulated during melanoma initiation and progression to locally
advanced and metastatic disease states. The combination of different
drugs targeting distinct pathways or gene products altered during mel-
anoma development may constitute more promising therapeutic strat-
egies than the use of a single therapeutic approach [6,14,58]. Therefore,
balancing efﬁcacy and toxicity of the use of an appropriate combination
of DLK1 and/or DLK2 proteins with conventional chemotherapy might
be considered as a research avenue to improve the treatment of mela-
noma in the future.
In summary, our ﬁndings indicate that both DLK1 and DLK2 proteins
regulate metastatic melanoma cell proliferation in a dose-dependent
manner. Besides, our data revealed that the level of NOTCH signaling,
which can be regulated by DLK proteins and their combined treatment
with NOTCH signaling inhibitors, such as DAPT, can lead to opposite
effects in metastatic melanoma cell growth. Interestingly, we show
that insufﬁcient inhibition of NOTCH signaling may promote tumor
Fig. 6.NOTCH activation and signaling in SK-MEL-2 cells treatedwith the γ-secretase inhibitor DAPT and/or DLK proteins. (A) Analysis of active NOTCH1 protein (active NICD1 ~ 110 kDa)
in the presence of the γ-secretase inhibitor DAPT at the indicated concentrations. A representativeWestern blot assay is shown (left). NICD1 expression was normalized to total NOTCH1
expression (~120 kDa) and data were ﬁnally normalized to those obtained from cells non-treatedwith DAPT. These data were represented in the graph (right) as themean± SD of three
independent experiments. (B) Analysis of NOTCH transcriptional activity, as measured by luciferase assays, in SK-MEL-2 cells transiently co-transfected with pGLucWT and empty vector
orHDLK1S, HDLK2S orHDLK2aS plasmids. Empty vector transfectantswere treatedwith DAPT at the indicated concentrations. These datawere represented in the graph as themean±SD
of three independent experiments. Student's t-test results relative to vector cells without DAPT treatment. (C) RepresentativeWestern blot analysis (left) of active NICD1 protein in stable
SK-MEL-2 transfectants overexpressing DLK1 or DLK2 and treated, or not, with DAPT at the indicated concentrations. NICD1 expression (~110 kDa) was normalized to total NOTCH1
expression (~120 kDa) and data were ﬁnally normalized to those obtained from cells transfected with the empty vector. These data were represented in the graph as the mean ± SD
of two different transfectants for each construct, in at least three independent experiments. Student's t-test results relative to cell samples are indicated in the ﬁgure. (D) Analysis of
NOTCH transcriptional activity, asmeasured by luciferase assays, in SK-MEL-2 cells transiently co-transfectedwith pGLucWT and empty vector or plasmids HDLK1S or HDLK2S, and treat-
ed, or not, with the γ-secretase inhibitor DAPT at the indicated concentrations. The relative luciferase activities were calculated by normalizing the data to those obtained from cells
transfectedwith the empty vector and treated, or not, with DAPT, and theywere represented as themean± SD of two different transfectants for each construct, in at least three indepen-
dent experiments. Student's t-test results relative to cell samples are indicated in the ﬁgure: *(P b 0.05), **(P b 0.01), ***(P b 0.001).
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Fig. 7. Effects of DLK1 or DLK2 overexpression and/or DAPT treatment in SK-MEL-2 cell proliferation. Proliferation rate, as measured by MTT assays, of SK-MEL-2 cells stably transfected
with the empty vector (A), HDLK1S (B), or HDL2S (C), in the presence of the γ-secretase inhibitor DAPT at the indicated concentrations. Themeans± SD of two different transfectants for
each construct in at least three independent experiments are plotted. The number of cells in the different time points was normalized to the number of cells at time zero, set arbitrarily at 1.
Student's t-test results relative to non-treated cells: *(P b 0.05), **(P b 0.01), ***(P b 0.001).
2683M.-L. Nueda et al. / Biochimica et Biophysica Acta 1843 (2014) 2674–2684cell growth, an effect that needs to be considered in the design of clinical
trials and patient treatment strategies. Finally, the data presented here
suggest that the use of a correct combination of GSIs and DLK proteins
or related peptides might be a favorable strategy for NOTCH-targeted
cancer therapies in the future.
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